Salute e Benessere
LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly
"We congratulate Frank and the Remedium team on this important milestone with Lilly," said Andrew Worden , Founding Partner at Lifespan Vision Ventures. "It is a powerful validation of their platform and is an important step toward developing interventions that extend healthspan. We're excited to support Remedium as they scale their platform and translate it into therapies that can benefit millions of patients."
Remedium Bio is advancing a new generation of gene therapies to address major unmet medical needs across endocrinology, immunology, neurology, and musculoskeletal diseases. Its proprietary Prometheus™ platform enables long-lasting, adjustable-dose delivery of therapeutic genes through a single subcutaneous injection. This approach has the potential to replace many protein-based treatments at significantly lower cost, while offering patients safe, durable, and tunable control over therapeutic protein expression. Remedium's pipeline includes multiple programs with the potential to meaningfully reshape the treatment landscape for conditions such as obesity and Type 2 diabetes.
For more information, visit: www.remedium-bio.com
Lifespan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space. Our mission is to support and accelerate the development of innovative therapies that extend healthspan, improve quality of life as individuals age, and address age-related challenges. Through strategic partnerships and investments, we aim to shape a future where advances in science and technology prevent, delay, and treat age-related diseases; ultimately enabling healthier, longer lives.
Contact: info@lifespanvision.com
Logo - https://mma.prnewswire.com/media/1780796/LifeSpan_Vision_Ventures_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lifespan-portfolio-company-remedium-signs-landmark-deal-with-eli-lilly-302564703.html